The following is a summary of the NeurAxis, Inc. (NRXS) Q4 2023 Earnings Call Transcript:

Financial Performance:

• NeurAxis experienced a decrease in revenues in fiscal year 2023 to $2.5 million, down 8.4% from the previous year, predominantly due to reduced shipments.

• Q4 revenues saw a drop to $531.5 thousand compared to $613.1 thousand in Q4 2022.

• Despite a reduction in selling expenses to $323.6 thousand from prior year's $410.9 thousand, the company's net loss heightened to $14.6 million in 2023, much higher than the $4.8 million loss in 2022.

• The Q4 net loss stood at $5.3 million, mainly because of a $3.7 million debt extinguishment cost and higher G&A expenses.

• The company's financial restatement for certain periods in 2023 resulted in an upshot of $3.7 million in the net loss and an equal increase to additional paid-in-capital.

Business Progress:

• The company treated 830 children using its IB-Stim technology in 2023, marking a penetration rate of 0.14%.

• NeurAxis noted significant growth in insurance coverage and plans for further expansion in the following year.

• Working towards acquiring a Category 1 billing code, the company already has a technology-specific one.

• After securing $6.1 million in convertible financing, the company intends to commercialize additional devices like the RED, expecting its FDA clearance in the fall of 2024.

• NeurAxis expects a rise in its revenues, powered by expanding insurance coverage and the launch of RED device, projecting a more profound growth wave into 2024 and 2025.

• The company is strategically focusing on market education, wider insurance acceptance, and commercializing its RED technology to enable swift growth. The introduction of RED technology is anticipated to serve as a significant revenue driver. Despite a Q4 revenue dip, the company is diversifying its customer base and optimistically sees this as a move towards improved insurance coverage and reimbursement rates.

More details: Neuraxis IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.